MedTrace Logo

Benign Prostatic Hyperplasia in Taiwan

NCT00941343 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 362

Last updated 2010-03-30

No results posted yet for this study

Summary

Primary Objective:

* To assess the sexual function of Benign Prostatic Hyperplasia patients

Secondary Objective:

* To evaluate the association between Lower Urinary Tract Symptoms severity and sexual disorders
* To compare the sexual function, urinary symptoms and Quality of Life of Benign Prostatic Hyperplasia patients on XATRAL 10mg OD among the different regions
* To correlate the Male Sexual Health Questionnaire(MSHQ) and 5-item version of the International Index of Erectile Function (IIEF-5)
* To assess the onset of action of XATRAL 10mg OD
* To assess the peak urinary flow rate
* To assess the safety and the tolerability of XATRAL 10mg OD

Conditions

  • Prostatic Diseases

Interventions

DRUG

Alfuzosin (XATRAL® - SL770499)

One tablet of XATRAL® 10mg OD once a day at the end of an evening meal. The tablets had to be swallowed whole without being chewed or crushed

Sponsors & Collaborators

Principal Investigators

  • Sharon Chang · Sanofi

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00941343 on ClinicalTrials.gov